The Importance of Imaging to Identify Early Signs of Intraocular Inflammation Expert Opinion for Brolucizumab

Due to this being a letter, abstract was not needed based on author guidelines.

[1]  F. Holz,et al.  Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study , 2021, British Journal of Ophthalmology.

[2]  U. Pleyer,et al.  [Intraocular inflammation with brolucizumab use : Patient management-diagnosis-therapy]. , 2021, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[3]  M. Kaya,et al.  Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection , 2021, Turkish journal of ophthalmology.

[4]  Ivana K. Kim,et al.  Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: post-hoc review of HAWK and HARRIER. , 2020, Ophthalmology.

[5]  Rishi P. Singh,et al.  HAWK and HARRIER: 96-Week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. , 2020, Ophthalmology.

[6]  Lejla Vajzovic,et al.  Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. , 2020, Ophthalmology.

[7]  J. P. Greenberg,et al.  Aflibercept-Related Sterile Intraocular Inflammation Outcomes. , 2019, Ophthalmology. Retina.

[8]  X. Xia,et al.  Advances in Retinal Optical Imaging , 2018, Photonics.

[9]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[10]  E. Souied,et al.  Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis , 2016, Ophthalmic epidemiology.

[11]  Francesco Bandello,et al.  Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA) , 2014, British Journal of Ophthalmology.

[12]  M. Franzblau,et al.  Conflict of Interest Statement , 2004 .

[13]  U. Schmidt-Erfurth,et al.  HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. , 2019, Ophthalmology.